Collaboration

Innovent, Pfizer partner on 12 early-stage cancer programs

Fri, 29 May 2026 09:00:00 -0400

Innovent Biologics Inc. and Pfizer Inc. have entered into a strategic global licensing and collaboration agreement for the research and development of 12 new breakthrough early-stage and de novo cancer medicines.

Biomunex enters AI partnerships to advance cancer immunotherapies

Wed, 27 May 2026 09:00:00 -0400

Biomunex Pharmaceuticals SAS has entered into strategic collaborations with two AI-specialized companies – Gordion Bioscience Inc. and Tangramed Biotech SAS – as part of its strategy to integrate AI into its R&D activities and support the development of next-generation immunotherapies in oncology.

Circio and Aavigen to collaborate on targeted cardiac AAVs

Wed, 27 May 2026 09:00:00 -0400

Circio Holding ASA and Aavigen GmbH have entered a research collaboration focused on developing circVec-enhanced AAV vectors engineered for targeted, low-dose gene therapies for heart diseases.

Launch of CGTxchange to reactivate cell and gene therapy programs

Fri, 15 May 2026 09:00:00 -0400

The American Society of Gene & Cell Therapy (ASGCT) and Orphan Therapeutics Accelerator (OTXL) have announced the public launch of CGTxchange, an AI-enhanced clearinghouse and marketplace built to help reactivate cell and gene therapy programs that have been shelved despite strong scientific and clinical evidence.

Andzonbio2 enters neuroinflammation collaboration

Thu, 14 May 2026 09:00:00 -0400

Andzonbio2 has signed agreements with the Alborada Drug Discovery Institute (ADDI) at the University of Cambridge and Cambridge Enterprise to advance a new class of therapeutics targeting neuroinflammation, a central driver of multiple neurodegenerative and neurological conditions.

AOP Health and VRG Therapeutics partner on immunology program

Wed, 13 May 2026 09:00:00 -0400

AOP Orphan Pharmaceuticals GmbH (AOP Health) has established a strategic partnership with VRG Therapeutics Zrt to advance a novel Kv1.3 potassium channel inhibitor for use in inflammation and immunology indications.

UCB and Cancer Research UK enter new oncology alliance

Thu, 07 May 2026 09:00:00 -0400

UCB SA has entered into a new multiproject strategic alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons, to advance a pipeline of novel investigational oncology candidates.

Apertura Gene Therapy and TSC Alliance partner on gene therapies

Wed, 06 May 2026 09:00:00 -0400

Apertura Gene Therapy LLC and the TSC Alliance have established a collaboration to advance gene therapy programs designed to treat tuberous sclerosis complex (TSC).

Elaaj Bio advances gene therapy for CDKL5 deﬁciency disorder

Wed, 06 May 2026 09:00:00 -0400

Elaaj Bio, a wholly owned subsidiary of the nonproﬁt Loulou Foundation, has entered into a partnership with Viralgen Vector Core SL to advance a gene therapy program for CDKL5 deﬁciency disorder.

Genomics and Greywolf partner in autoimmune diseases

Thu, 30 Apr 2026 09:00:00 -0400

Genomics Ltd. has established a strategic relationship with Grey Wolf Therapeutics Ltd. (Greywolf) to develop first-in-class treatments for autoimmune diseases.

Astrazeneca exercises option for Pinetree’s PTX-299

Thu, 30 Apr 2026 09:00:00 -0400

Astrazeneca plc has exercised an option under its collaboration with Pinetree Therapeutics Inc. to obtain an exclusive global license to develop and commercialize PTX-299, a first-in-class bispecific antibody degrader targeting EGFR. The option exercise triggers a $25 million payment to Pinetree.

Milestone in Atrium and BMS cardiovascular collaboration

Fri, 24 Apr 2026 09:00:00 -0400

Atrium Therapeutics Inc. has earned a $15 million development milestone payment from Bristol Myers Squibb Co. (BMS) for the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the companies’ ongoing collaboration.

Entos and L-CMD Research Foundation collaborate

Tue, 21 Apr 2026 09:00:00 -0400

Entos Pharmaceuticals Inc. has established a collaboration with the L-CMD Research Foundation with the aim of developing a curative therapy for LMNA-related congenital muscular dystrophy (L-CMD).

Biogen to use Alloy Therapeutics’ Anticlastic ASO platform

Wed, 08 Apr 2026 09:00:00 -0400

Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. for the use of Alloy’s Anticlastic ASO platform to accelerate the development of innovative oligonucleotide therapeutics.

Akari Therapeutics partners with Wuxi XDC on ADC payload

Tue, 07 Apr 2026 09:00:00 -0400

Akari Therapeutics plc has established a strategic partnership with Wuxi XDC Cayman Inc. to accelerate the development of Akari’s novel PH1 payload. Akari’s lead program, AKTX-101, is initially targeting metastatic urothelial cancer.

Insilico Medicine and Aska enter gynecological collaboration

Wed, 25 Mar 2026 09:00:00 -0400

Insilico Medicine Cayman Topco has established a strategic research collaboration with Aska Pharmaceutical Co. Ltd. to identify novel therapeutic targets for challenging gynecological conditions, including endometriosis, uterine fibroids and adenomyosis.

Insitro and Bristol Myers Squibb expand ALS collaboration

Tue, 24 Mar 2026 09:00:00 -0400

Insitro Inc. has expanded its strategic collaboration with Bristol Myers Squibb Co. to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS).

Glyconex and Nippon Kayaku collaborate on GNX201-ADC

Tue, 24 Mar 2026 09:00:00 -0400

Glyconex Inc. has entered into a collaboration agreement with Nippon Kayaku Co. Ltd. to advance GNX201-ADC, a next-generation glycan-directed antibody-drug conjugate (ADC) candidate for the treatment of solid tumors.

New Danish research program targets α-synuclein in Parkinson’s

Mon, 23 Mar 2026 09:00:00 -0400

A new Danish research project focused on Parkinson’s disease has received funding from Innovation Fund Denmark. The DESYNA (Degradation of Extracellular α-SYNuclein Aggregates) project aims to develop a new therapy targeting α-synuclein, the accumulation of which is a key driver of Parkinson’s disease.

Alloy Therapeutics and Abbvie partner on antibody platform

Tue, 17 Mar 2026 09:00:00 -0400

Alloy Therapeutics Inc. has entered into an agreement with Abbvie Inc. to develop a new antibody platform to discover antibodies against targets that are difficult to address with current technologies.

Aptar and Covirix Medical collaborate on inhaled antivirals

Fri, 13 Mar 2026 09:00:00 -0400

Aptar Pharma, part of Aptargroup Inc., has established a technical collaboration with Covirix Medical Pty Ltd. under a letter of intent to develop inhaled antiviral treatments.

Newcelx partners with Eledon to advance NCEL-101

Mon, 09 Mar 2026 09:00:00 -0400

Newcelx Ltd. has entered into a collaborative research agreement with Eledon Pharmaceuticals Inc. with the aim of advancing its lead program, NCEL-101, for type 1 diabetes.

Zelluna, Etcembly partner on AI-enabled T-cell receptor engineering

Mon, 09 Mar 2026 09:00:00 -0400

Zelluna ASA has established a collaboration with Etcembly Ltd. that will focus on the engineering of high-affinity, tumor-specific T-cell receptors targeting KKLC1.

Sinopia and Ono collaborate in metabolic disorders

Wed, 04 Mar 2026 08:00:00 -0500

Sinopia Biosciences Inc. has entered into a target discovery collaboration with Ono Pharmaceutical Co. Ltd. focused on a group of rare metabolic disorders with significant unmet medical need.

Antiverse announces series A financing, tie-up with CF Foundation

Wed, 04 Mar 2026 08:00:00 -0500

Antiverse Ltd. has announced the close of a $9.3 million series A financing. The funding will support expansion of the company’s proprietary AI antibody design platform, accelerate development of its internal therapeutic pipeline, and advance lead antibody programs toward in vivo efficacy studies.

Ono and Congruence expand drug discovery collaboration

Tue, 03 Mar 2026 08:00:00 -0500

Ono Pharmaceutical Co. Ltd. has entered into an agreement to expand its drug discovery collaboration agreement with Congruence Therapeutics Inc. for the discovery of novel small-molecule modulators against multiple protein targets in the areas of neurology and immunology.

Cure Rare Disease signs ANO5-related disease partnership

Tue, 03 Mar 2026 08:00:00 -0500

Cure Rare Disease has entered into a multiyear partnership with the LGMD2L Foundation to develop a gene replacement therapy for anoctamin 5 (ANO5)-related disease, a rare genetic disorder.

Angelini and Quiver Bioscience partner in genetic epilepsies

Tue, 24 Feb 2026 08:00:00 -0500

Angelini Pharma SpA and Quiver Bioscience Inc. have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. Under the multiyear collaboration, Angelini Pharma will leverage Quiver’s technology platform to gain deeper understanding of a broad set of developmental and epileptic encephalopathies.

Financing at Gelmedix supports GMX-101 for geographic atrophy

Wed, 18 Feb 2026 08:00:00 -0500

Gelmedix Inc. has completed a $13 million seed financing to support progression of the company’s lead program, GMX-101, a retinal pigment epithelial (RPE) cell therapy to treat late-stage geographic atrophy.

Nektar Therapeutics and UCSF explore TNFR2 agonism in MS

Wed, 18 Feb 2026 08:00:00 -0500

Nektar Therapeutics Inc. has established an academic research collaboration with the University of California, San Francisco (UCSF) to explore the role of tumor necrosis factor receptor 2 (TNFR2) agonism in models of multiple sclerosis (MS) with the aim of supporting progression of NKTR-0165, Nektar’s first-in-class TNFR2 agonist antibody.